Back to results
US 11,077,194 B2Granted
Nitric oxide releasing pharmaceutical compositions
AssigneeNovan, Inc.
InventorRyan Doxey
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.
Claims22
A nitric oxide (NO)-releasing pharmaceutical composition, the NO-releasing pharmaceutical composition comprising:
- a hydrophobic base present in the NO-releasing pharmaceutical composition at a concentration from about 35% to about 90% by weight of the NO-releasing pharmaceutical composition;
- an amphiphilic compound present in the NO-releasing pharmaceutical composition at a concentration from about 1% to about 30% by weight of the NO-releasing pharmaceutical composition, wherein the amphiphilic compound is a polyethylene glycol (PEG) caprylic/capric glyceride;
- water at a concentration of less than about 2% by weight of the NO-releasing pharmaceutical composition;
- and
- an active pharmaceutical ingredient, wherein the active pharmaceutical ingredient consists of diazeniumdiolate-functionalized polysiloxane macromolecules that are NO-releasing co-condensed silica particles.
2 more elements
A pharmaceutical composition for topical delivery of nitric oxide, the composition comprising:
- an active pharmaceutical ingredient;
- a hydrophobic base comprising:
- a first hydrophobic base present in the composition at a concentration from 35% to 80% by weight of the composition, wherein the first hydrophobic base comprises a hydrophobic hydrocarbon polymer;
- and
- a second hydrophobic base present in the composition at a concentration from 1% to 20% by weight of the composition, wherein the second hydrophobic base is mineral oil;
- and
- an amphiphilic compound present in the composition at a concentration from 1% to 20% by weight of the composition, wherein the amphiphilic compound is a polyethylene glycol (PEG) caprylic/capric glyceride;
- wherein the active pharmaceutical ingredient consists of diazeniumdiolate-functionalized polysiloxane macromolecules that are nitric oxide (NO)-releasing co-condensed silica particles and the diazeniumdiolate-functionalized polysiloxane macromolecules are present in the composition at a concentration of up to 35% by weight of the composition, and
- wherein the composition has a NO content in a range of 0.27% to 3.30% by weight of the composition.
6 more elements
Dependencies are inferred from the claim text.